These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33891604)

  • 1. Evaluation of [Cys(ATTO 488)8]Dermorphin-NH2 as a novel tool for the study of μ-opioid peptide receptors.
    Giakomidi D; Bird MF; McDonald J; Marzola E; Guerrini R; Chanoch S; Sabu N; Horley B; Calo G; Lambert DG
    PLoS One; 2021; 16(4):e0250011. PubMed ID: 33891604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).
    Bird MF; Cerlesi MC; Brown M; Malfacini D; Vezzi V; Molinari P; Micheli L; Di Cesare Mannelli L; Ghelardini C; Guerrini R; Calò G; Lambert DG
    PLoS One; 2016; 11(6):e0156897. PubMed ID: 27272042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MOP and NOP receptor interaction: Studies with a dual expression system and bivalent peptide ligands.
    Bird MF; McDonald J; Horley B; O'Doherty JP; Fraser B; Gibson CL; Guerrini R; Caló G; Lambert DG
    PLoS One; 2022; 17(1):e0260880. PubMed ID: 35061679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.
    Bird MF; Vardanyan RS; Hruby VJ; Calò G; Guerrini R; Salvadori S; Trapella C; McDonald J; Rowbotham DJ; Lambert DG
    Br J Anaesth; 2015 Apr; 114(4):646-56. PubMed ID: 25680364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
    Tzschentke TM; Rutten K
    Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human peripheral blood mononuclear cells express nociceptin/orphanin FQ, but not mu, delta, or kappa opioid receptors.
    Williams JP; Thompson JP; McDonald J; Barnes TA; Cote T; Rowbotham DJ; Lambert DG
    Anesth Analg; 2007 Oct; 105(4):998-1005, table of contents. PubMed ID: 17898379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of the bifunctional opioid ligand H-Dmt-Tic-Gly-NH-Bzl (UFP-505).
    Dietis N; McDonald J; Molinari S; Calo G; Guerrini R; Rowbotham DJ; Lambert DG
    Br J Anaesth; 2012 Feb; 108(2):262-70. PubMed ID: 22194444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid-Modulated Receptor Localization and Erk1/2 Phosphorylation in Cells Coexpressing μ-Opioid and Nociceptin Receptors.
    Zhuo GY; Chen MC; Lin TY; Lin ST; Chen DT; Lee CW
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescent opioid receptor ligands as tools to study opioid receptor function.
    Giakomidi D; Bird MF; Guerrini R; Calo G; Lambert DG
    J Pharmacol Toxicol Methods; 2022; 113():107132. PubMed ID: 34728348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dermorphin-based potential affinity labels for mu-opioid receptors.
    Choi H; Murray TF; Aldrich JV
    J Pept Res; 2003 Jan; 61(1):40-5. PubMed ID: 12472847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nociceptin/Orphanin FQ (N/OFQ) conjugated to ATTO594: a novel fluorescent probe for the N/OFQ (NOP) receptor.
    Bird MF; Guerrini R; Willets JM; Thompson JP; Caló G; Lambert DG
    Br J Pharmacol; 2018 Dec; 175(24):4496-4506. PubMed ID: 30276802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine-elicited alteration of adenylate cyclase activity in human embryonic kidney 293 cells coexpressing κ-, μ-opioid and nociceptin receptors.
    Wang PC; Ho IK; Lee CW
    J Cell Mol Med; 2015 Nov; 19(11):2587-96. PubMed ID: 26153065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation and visualisation of [3H]dermorphin binding to mu opioid receptors in the rat brain. Combined high selectivity and affinity in a natural peptide agonist for the morphine (mu) receptor.
    Amiche M; Sagan S; Mor A; Pelaprat D; Rostene W; Delfour A; Nicolas P
    Eur J Biochem; 1990 May; 189(3):625-35. PubMed ID: 2161761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
    Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
    J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
    Olianas MC; Concas D; Onali P
    Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimeric dermorphin analogues as mu-receptor probes on rat brain membranes. Correlation between central mu-receptor potency and suppression of gastric acid secretion.
    Lazarus LH; Guglietta A; Wilson WE; Irons BJ; de Castiglione R
    J Biol Chem; 1989 Jan; 264(1):354-62. PubMed ID: 2562839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for nociceptin/orphanin FQ (NOP) but not µ (MOP), δ (DOP) or κ (KOP) opioid receptor mRNA in whole human blood.
    Al-Hashimi M; McDonald J; Thompson JP; Lambert DG
    Br J Anaesth; 2016 Mar; 116(3):423-9. PubMed ID: 26865135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nociceptin/orphanin FQ opioid peptide (NOP) receptor and µ-opioid peptide (MOP) receptors both contribute to the anti-hypersensitive effect of cebranopadol in a rat model of arthritic pain.
    Schiene K; Schröder W; Linz K; Frosch S; Tzschentke TM; Jansen U; Christoph T
    Eur J Pharmacol; 2018 Aug; 832():90-95. PubMed ID: 29753041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nociceptin/Orphanin FQ receptor expression in primary human umbilical vein endothelial cells is not regulated by exposure to breast cancer cell media or angiogenic stimuli.
    Giakomidi D; Khemiri S; Mahbuba W; McVey DG; Al-Janabi F; Guerrini R; Calo G; Ye S; Lambert DG
    BJA Open; 2022 Dec; 4():100110. PubMed ID: 37588788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hot topics in opioid pharmacology: mixed and biased opioids.
    Azzam AAH; McDonald J; Lambert DG
    Br J Anaesth; 2019 Jun; 122(6):e136-e145. PubMed ID: 31010646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.